ArticleCaspian journal of internal medicine2025
Predictive value of serum thyroglobulin after surgery and prior to I-131 therapy in patients with differentiated thyroid carcinoma, examined at two different time intervals.
Article in Caspian journal of internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Differentiated thyroid carcinoma (DTC) comprises nearly 90% of all thyroid malignancies. The main focus of our study was to examine how measuring Tg at multiple time points could predict the persistence and/or recurrence of both local and distant diseases. Methods: In this retrospective, single-center, observational study, we examined records of all patients who underwent total thyroidectomy for DTC and received radioactive iodine (RAI) ablation/therapy at the Nuclear Medicine of Shahid Beheshti Hospital. Blood samples were collected at two time, approximately 30 days before RAI (Tg-30 and TSH-30) and the same day of RAI, after TSH-stimulation (Tg-0 and TSH-0). During the follow-up period, patients were categorized into the four groups according to the ATA guideline. Group with an excellent response (ER), nodal disease (ND), distant disease (DD) and partial response (PR). Results: A significant difference between Tg-0 and Tg-30 was observed only in the ER group and the other 3 groups (p<0.001), and no significant difference was observed between the remaining 3 groups (p>0.05). Cut-off point of 1.35 ng/mL for the Tg-30 and 4.7 ng/mL for the Tg-0 was used with best sensitivity and specificity for differentiation of ER vs. ND. A cut-off point of 14.25 ng/mL for the Tg-30 and 40 ng/mL for the Tg-0 was able to correctly identify ER vs. DD. Conclusion: By using the cut-off values obtained in this study, it is possible to more accurately predict local or distant recurrences. Maybe these patients need a shorter follow-up period that leads to more appropriate treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.